Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100

SIMPLE SUMMARY: There is an unmet need for novel anticancer therapeutics that work differently to current standard-of-care therapies. BOLD-100 is a unique clinical-stage anticancer compound that is based on the rare metal, ruthenium. Understanding the bioactivity of BOLD-100 can accelerate its devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Brian J., Raha, Paromita, Pankovich, Jim, Bazett, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817855/
https://www.ncbi.nlm.nih.gov/pubmed/36612025
http://dx.doi.org/10.3390/cancers15010028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817855/
https://www.ncbi.nlm.nih.gov/pubmed/36612025
http://dx.doi.org/10.3390/cancers15010028

Ejemplares similares